324 related articles for article (PubMed ID: 31614472)
1. Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors.
Oh S; Lee JH; Kwack K; Choi SW
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614472
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.
Lupo KB; Matosevic S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31163679
[TBL] [Abstract][Full Text] [Related]
3. Present and Future of Allogeneic Natural Killer Cell Therapy.
Lim O; Jung MY; Hwang YK; Shin EC
Front Immunol; 2015; 6():286. PubMed ID: 26089823
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.
Nayyar G; Chu Y; Cairo MS
Front Oncol; 2019; 9():51. PubMed ID: 30805309
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Haspels HN; Rahman MA; Joseph JV; Gras Navarro A; Chekenya M
Front Immunol; 2018; 9():1345. PubMed ID: 29967607
[TBL] [Abstract][Full Text] [Related]
6. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro.
Ahn YO; Kim S; Kim TM; Song EY; Park MH; Heo DS
J Immunother; 2013 Sep; 36(7):373-81. PubMed ID: 23924789
[TBL] [Abstract][Full Text] [Related]
7. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
8. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.
Zaghi E; Calvi M; Marcenaro E; Mavilio D; Di Vito C
J Leukoc Biol; 2019 Jun; 105(6):1243-1251. PubMed ID: 30645023
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
10. Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects.
Wang X; Yang X; Wang Y; Chen Y; Yang Y; Shang S; Wang W; Wang Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612246
[TBL] [Abstract][Full Text] [Related]
11. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
13. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.
Dahlberg CI; Sarhan D; Chrobok M; Duru AD; Alici E
Front Immunol; 2015; 6():605. PubMed ID: 26648934
[TBL] [Abstract][Full Text] [Related]
15.
Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
[TBL] [Abstract][Full Text] [Related]
16. The Molecular Imaging of Natural Killer Cells.
Shapovalova M; Pyper SR; Moriarity BS; LeBeau AM
Mol Imaging; 2018; 17():1536012118794816. PubMed ID: 30203710
[TBL] [Abstract][Full Text] [Related]
17. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
18. The role of NK cells in HIV-1 protection: autologous, allogeneic or both?
Hens J; Jennes W; Kestens L
AIDS Res Ther; 2016; 13():15. PubMed ID: 26997965
[TBL] [Abstract][Full Text] [Related]
19. The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection.
Rajalingam R
Front Immunol; 2016; 7():585. PubMed ID: 28066408
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
